Compare CAVA & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAVA | BIO |
|---|---|---|
| Founded | 2006 | 1952 |
| Country | United States | United States |
| Employees | N/A | 7700 |
| Industry | Restaurants | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 8.2B |
| IPO Year | 2023 | N/A |
| Metric | CAVA | BIO |
|---|---|---|
| Price | $60.20 | $304.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 4 |
| Target Price | $78.84 | ★ $358.50 |
| AVG Volume (30 Days) | ★ 3.5M | 155.9K |
| Earning Date | 11-04-2025 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 151.16 | N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | $1,132,074,000.00 | ★ $2,557,500,000.00 |
| Revenue This Year | $24.00 | $1.62 |
| Revenue Next Year | $20.42 | $2.26 |
| P/E Ratio | $51.88 | ★ N/A |
| Revenue Growth | ★ 23.93 | N/A |
| 52 Week Low | $43.41 | $211.43 |
| 52 Week High | $144.49 | $373.69 |
| Indicator | CAVA | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 67.09 | 44.66 |
| Support Level | $51.52 | $298.78 |
| Resistance Level | $62.16 | $307.07 |
| Average True Range (ATR) | 2.13 | 7.77 |
| MACD | 1.03 | -0.88 |
| Stochastic Oscillator | 81.92 | 35.90 |
Cava Group Inc owns and operates a chain of restaurants. It is the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: CAVA and Zoes Kitchen. The company generates all of its revenue from the CAVA segment.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.